Table 2.
irAEs | Nivolumab | Nivolumab + Ipilimumab | Total | |||
---|---|---|---|---|---|---|
n | % | n | % | n | % | |
Pneumonitis | 3 | 9.1% | 0 | 0.0% | 5 | 6.9% |
Colitis (diarrhea) | 5 | 15.1% | 0 | 0.0% | 5 | 11.6% |
Hepatitis | 4 | 12.1% | 3 | 30,0% | 7 | 16.3% |
Skin reactions | 8 | 24.2% | 1 | 10.0% | 9 | 20.9% |
Nephritis | 0 | 0.0% | 1 | 10.0% | 1 | 2.3% |
Arthralgia/myalgia | 4 | 12.1% | 0 | 0,0% | 4 | 9.3% |
Endocrine-related events | 14 | 42.4% | 6 | 60.0% | 20 | 46.5% |